Clinical Case Series - Lymphoma 2 - Question 2

When a patient on ibrutinib develops non–life-threatening side effects, but their disease is responding to therapy, what is your preferred initial course of action?
Continue treatment at the current dose, and try to manage toxicity with supportive care
Decrease the dose, and try to manage toxicity with supportive care
Interrupt therapy, and try to manage toxicity with supportive care
Switch to a treatment with the same mechanism of action but a different toxicity profile
Switch to a treatment with a different mechanism of action
{"name":"Clinical Case Series - Lymphoma 2 - Question 2", "url":"https://www.poll-maker.com/QWILVXZAK","txt":"When a patient on ibrutinib develops non–life-threatening side effects, but their disease is responding to therapy, what is your preferred initial course of action?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys